Janus Kinase (JAK) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2017
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Janus Kinase (JAK) Inhibitors- Competitive Landscape, Pipeline and Market Analysis, 2017”, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Janus Kinase (JAK) Inhibitors. This report provides information on the therapeutic development based on Janus Kinase (JAK) Inhibitors mechanism of action dealing with around 35+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight’s Report also assesses the Janus Kinase (JAK) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 25+ active companies involved in the therapeutic development of the products.
SCOPE
DelveInsight’s, “Janus Kinase (JAK) Inhibitors- Competitive Landscape, Pipeline and Market Analysis, 2017”, report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Janus Kinase (JAK) Inhibitors. This report provides information on the therapeutic development based on Janus Kinase (JAK) Inhibitors mechanism of action dealing with around 35+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight’s Report also assesses the Janus Kinase (JAK) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 25+ active companies involved in the therapeutic development of the products.
SCOPE
- The report provides competitive pipeline landscape of Janus Kinase (JAK) Inhibitors
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for Janus Kinase (JAK) Inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Janus Kinase (JAK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Janus Kinase (JAK) Inhibitors and also provide company profiling
- The report also gives the information of dormant pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Complete MOA intelligence and complete understanding over therapeutics development for Janus Kinase (JAK) Inhibitors
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding Janus Kinase (JAK) Inhibitors pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Introduction
Executive Summary
Executive Summary Snapshot
Janus kinase Inhibitors (JAK Inhibitors) Overview
Introduction
Structure and Mechanism
Janus Kinase Inhibitors
Types of JAK Inhibitors
Cytokines associated with Janus kinases and result of their mutations
JAK Inhibitors Market Analysis
Collaborations and Deals
Acquisition Deals
Designations Analysis
Grants
Financing
Companies Involved in JAK Inhibitor Development
Therapeutic Targets by Company and Indication
Market Drivers and Barriers
Drivers
Barriers
Marketed Products
Therapeutics under Development by Companies
Late Stage Products (Filed &Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase Iand IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant Products
Companies involved in Therapeutics Development
Upcoming Conferences
SWOT Analysis for JAK Inhibitors
Appendix
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer
Executive Summary
Executive Summary Snapshot
Janus kinase Inhibitors (JAK Inhibitors) Overview
Introduction
Structure and Mechanism
Janus Kinase Inhibitors
Types of JAK Inhibitors
Cytokines associated with Janus kinases and result of their mutations
JAK Inhibitors Market Analysis
Collaborations and Deals
Acquisition Deals
Designations Analysis
Grants
Financing
Companies Involved in JAK Inhibitor Development
Therapeutic Targets by Company and Indication
Market Drivers and Barriers
Drivers
Barriers
Marketed Products
Therapeutics under Development by Companies
Late Stage Products (Filed &Phase III)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase Iand IND)
Comparative Analysis
Discovery and Pre-clinical stage Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant Products
Companies involved in Therapeutics Development
Upcoming Conferences
SWOT Analysis for JAK Inhibitors
Appendix
Methodology
Consulting Services
About DelveInsight
Contact Us
Disclaimer
LIST OF TABLES
Table 1:Collaboration and Deal Values for JAK Inhibitors, 2017
Table 2:Acquisition deals for the development of JAK Inhibitors, 2017
Table 3: Grants, 2017
Table 4:Number of Products Under Development for Janus Kinase (JAK) Inhibitors, 2017
Table 5: Number of Products under Development by Companies, 2017
Table 6: Late Stage Products (Filed &Phase III),2017
Table 7: Mid Stage Products (Phase II),2017
Table 8: Early Stage Products (Phase Iand IND), 2017
Table 9: Discovery and Pre-clinical stage Products, 2017
Table 10: Assessment by Monotherapy Products, 2017
Table 11: Assessment by Route Of Administration, 2017
Table 12:Assessment by Stage and Route Of Administration, 2017
Table 13: Assessment by Molecule Type, 2017
Table 14: Assessment by Stage and Molecule Type, 2017
Table 15: Dormant Products, 2017
Table 16: Discontinued Products, 2017
Table 17: AbbVie, Overview, 2017
Table 18: Aclaris Therapeutics, Inc., Overview, 2017
Table 19: Advinus Therapeutics, Overview, 2017
Table 20: Amgen Inc., Overview, 2017
Table 21: Aptose Biosciences, Overview, 2017
Table 22: Arrien Pharmaceuticals, Overview, 2017
Table 23: Asana BioSciences, Overview, 2017
Table 24: Astellas Pharma Inc., Overview, 2017
Table 25: Astrazeneca, Overview, 2017
Table 26:Bristol-Myers Squibb, Overview, 2017
Table 27: CleveXel Pharma, Overview, 2017
Table 28: Cloud pharmaceuticals, Overview, 2017
Table 29: Concert Pharmaceuticals, Overview, 2017
Table 30: CTI BioPharma, Overview, 2017
Table 31: Cytopia Research, Overview, 2017
Table 32: Eli Lilly and Company, Overview, 2017
Table 33: Galapagos NV, Overview, 2017
Table 34: Gilead Sciences, Overview, 2017
Table 35: Hoffmann-La Roche, Overview, 2017
Table 36: Incyte Corporation, Overview, 2017
Table 37: Japan Tobacco Company, Overview, 2017
Table 38: Nimbus Therapeutics, Overview, 2017
Table 39: Pfizer Inc., Overview, 2017
Table 40: Portola Pharmaceuticals, Overview, 2017
Table 41: Sareum Limited, Overview, 2017
Table 42: Theravance Biopharma, Overview, 2017
Table 43: Tragara Pharmaceuticals, Overview, 2017
Table 44: Vectura Group, Overview, 2017
Table 1:Collaboration and Deal Values for JAK Inhibitors, 2017
Table 2:Acquisition deals for the development of JAK Inhibitors, 2017
Table 3: Grants, 2017
Table 4:Number of Products Under Development for Janus Kinase (JAK) Inhibitors, 2017
Table 5: Number of Products under Development by Companies, 2017
Table 6: Late Stage Products (Filed &Phase III),2017
Table 7: Mid Stage Products (Phase II),2017
Table 8: Early Stage Products (Phase Iand IND), 2017
Table 9: Discovery and Pre-clinical stage Products, 2017
Table 10: Assessment by Monotherapy Products, 2017
Table 11: Assessment by Route Of Administration, 2017
Table 12:Assessment by Stage and Route Of Administration, 2017
Table 13: Assessment by Molecule Type, 2017
Table 14: Assessment by Stage and Molecule Type, 2017
Table 15: Dormant Products, 2017
Table 16: Discontinued Products, 2017
Table 17: AbbVie, Overview, 2017
Table 18: Aclaris Therapeutics, Inc., Overview, 2017
Table 19: Advinus Therapeutics, Overview, 2017
Table 20: Amgen Inc., Overview, 2017
Table 21: Aptose Biosciences, Overview, 2017
Table 22: Arrien Pharmaceuticals, Overview, 2017
Table 23: Asana BioSciences, Overview, 2017
Table 24: Astellas Pharma Inc., Overview, 2017
Table 25: Astrazeneca, Overview, 2017
Table 26:Bristol-Myers Squibb, Overview, 2017
Table 27: CleveXel Pharma, Overview, 2017
Table 28: Cloud pharmaceuticals, Overview, 2017
Table 29: Concert Pharmaceuticals, Overview, 2017
Table 30: CTI BioPharma, Overview, 2017
Table 31: Cytopia Research, Overview, 2017
Table 32: Eli Lilly and Company, Overview, 2017
Table 33: Galapagos NV, Overview, 2017
Table 34: Gilead Sciences, Overview, 2017
Table 35: Hoffmann-La Roche, Overview, 2017
Table 36: Incyte Corporation, Overview, 2017
Table 37: Japan Tobacco Company, Overview, 2017
Table 38: Nimbus Therapeutics, Overview, 2017
Table 39: Pfizer Inc., Overview, 2017
Table 40: Portola Pharmaceuticals, Overview, 2017
Table 41: Sareum Limited, Overview, 2017
Table 42: Theravance Biopharma, Overview, 2017
Table 43: Tragara Pharmaceuticals, Overview, 2017
Table 44: Vectura Group, Overview, 2017
LIST OF FIGURES
Figure 1: Structure of Janus Kinase
Figure 2: Illustrated mechanism of Janus Kinase
Figure 3: Collaboration and Deals for JAK Inhibitors, 2017
Figure 4: Number of Companies under acquisition for JAK Inhibitors, 2017
Figure 5: Designation Analysis for JAK Inhibitors, 2017
Figure 6: Grants, 2017
Figure 7: Number of Products under Development for JAK Inhibitor, 2017
Figure 8: Number of Products under Development for Janus Kinase(JAK) Inhibitors, 2017
Figure 9: Late Stage Products (Filed &Phase III),2017
Figure 10: Mid Stage Products (Phase II),2017
Figure 11:Early Stage Products (Phase Iand IND ), 2017
Figure 12: Discovery and Pre-clinical stage Products, 2017
Figure 13: Number of Products under Development forJAK Inhibitors,2017
Figure 14: Assessment by Route of Administration, 2017
Figure 15: Assessment by Stage and Route of Administration,2017
Figure 16: Assessment by Molecule Type,2017
Figure 17: Assessment by Stage and Molecule Type,2017
Figure 18: Dormant Products, 2017
Figure 19:Discontinued Products, 2017
Figure 1: Structure of Janus Kinase
Figure 2: Illustrated mechanism of Janus Kinase
Figure 3: Collaboration and Deals for JAK Inhibitors, 2017
Figure 4: Number of Companies under acquisition for JAK Inhibitors, 2017
Figure 5: Designation Analysis for JAK Inhibitors, 2017
Figure 6: Grants, 2017
Figure 7: Number of Products under Development for JAK Inhibitor, 2017
Figure 8: Number of Products under Development for Janus Kinase(JAK) Inhibitors, 2017
Figure 9: Late Stage Products (Filed &Phase III),2017
Figure 10: Mid Stage Products (Phase II),2017
Figure 11:Early Stage Products (Phase Iand IND ), 2017
Figure 12: Discovery and Pre-clinical stage Products, 2017
Figure 13: Number of Products under Development forJAK Inhibitors,2017
Figure 14: Assessment by Route of Administration, 2017
Figure 15: Assessment by Stage and Route of Administration,2017
Figure 16: Assessment by Molecule Type,2017
Figure 17: Assessment by Stage and Molecule Type,2017
Figure 18: Dormant Products, 2017
Figure 19:Discontinued Products, 2017
